Novo Nordisk A/S logged a 0.0% change during today's afternoon session, and is now trading at a price of $69.24 per share. The S&P 500 index moved -0.0%. NVO's trading volume is 6,608,699 compared to the stock's average volume of 8,934,228.
Novo Nordisk A/S trades -24.36% away from its average analyst target price of $91.54 per share. The 11 analysts following the stock have set target prices ranging from $61.07545 to $127.85614, and on average have given Novo Nordisk A/S a rating of buy.
Anyone interested in buying NVO should be aware of the facts below:
-
Novo Nordisk A/S's current price is -45.9% below its Graham number of $127.92, which implies the stock has a margin of safety
-
Novo Nordisk A/S has moved -44.4% over the last year, and the S&P 500 logged a change of 9.8%
-
Based on its trailing earnings per share of 3.43, Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 20.2 while the S&P 500 average is 29.3
-
NVO has a forward P/E ratio of 17.0 based on its forward 12 month price to earnings (EPS) of $4.07 per share
-
Its Price to Book (P/B) ratio is 2.14 compared to its sector average of 3.19
-
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
-
Based in Bagsvaerd, the company has 76,302 full time employees and a market cap of $306.34 Billion. Novo Nordisk A/S currently returns an annual dividend yield of 16.5%.
